{"title":"美国临床肿瘤学会第46届年会。","authors":"Asma Al-Shamahi, Lisa Murch, Konrad Kirkham","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The 46th Annual Meeting of the American Society of Clinical Oncology, held in Chicago, included topics covering new therapeutic developments in the field of oncology. This conference report highlights selected presentations on novel therapies for cancers including glioblastoma, breast cancer, myeloma, NSCLC and solid tumors. Investigational drugs discussed include rindopepimut and PF-299804 (both Pfizer Inc), entinostat (Syndax Pharmaceuticals Inc), panobinostat and NVP-LDE-225 (both Novartis AG), CHR-3996 (Chroma Therapeutics Ltd), and HGS-1029 (Human Genome Sciences Inc).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 8","pages":"506-9"},"PeriodicalIF":0.0000,"publicationDate":"2010-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"American Society of Clinical Oncology--46th annual meeting.\",\"authors\":\"Asma Al-Shamahi, Lisa Murch, Konrad Kirkham\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The 46th Annual Meeting of the American Society of Clinical Oncology, held in Chicago, included topics covering new therapeutic developments in the field of oncology. This conference report highlights selected presentations on novel therapies for cancers including glioblastoma, breast cancer, myeloma, NSCLC and solid tumors. Investigational drugs discussed include rindopepimut and PF-299804 (both Pfizer Inc), entinostat (Syndax Pharmaceuticals Inc), panobinostat and NVP-LDE-225 (both Novartis AG), CHR-3996 (Chroma Therapeutics Ltd), and HGS-1029 (Human Genome Sciences Inc).</p>\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 8\",\"pages\":\"506-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
American Society of Clinical Oncology--46th annual meeting.
The 46th Annual Meeting of the American Society of Clinical Oncology, held in Chicago, included topics covering new therapeutic developments in the field of oncology. This conference report highlights selected presentations on novel therapies for cancers including glioblastoma, breast cancer, myeloma, NSCLC and solid tumors. Investigational drugs discussed include rindopepimut and PF-299804 (both Pfizer Inc), entinostat (Syndax Pharmaceuticals Inc), panobinostat and NVP-LDE-225 (both Novartis AG), CHR-3996 (Chroma Therapeutics Ltd), and HGS-1029 (Human Genome Sciences Inc).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
